Venetoclax plus obinutuzumab as 1st line treatment may be beneficial and cost-effective – also for patients without del17p/TP53-mutation

From a health-economic perspective, it pays off to treat CLL patients without del17p/TP53 mutations with venetoclax plus obinutuzumab instead of chlorambucil plus obinutuzumab. Listen to Matilde Slot, health economist at the Nordic Institute for Health Economics in Aarhus, Denmark, explain the background for this conclusion directly from ASH22 in New Orleans.